SecBot SecBot
8-K ·Filed May 5, 2026

QTTB

Q32 Bio Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001193125-26-205006
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock is a binary event driven by mid-2026 SIGNAL-AA data. The extended cash runway into 1H 2028 removes near-term financing risk, but the $75M ATM filed 11 days ago adds overhang. Monitor for any early data disclosures or analyst days ahead of the topline readout.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.14
T+0 close · May 5, 2026 · via day close
Latest settled
+202.72%
T+60 · $15.56
Vs SPY
+199.98%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $5.14entry
  2. T+1 · 7mo ago +6.42%α +5.04% · $5.47
  3. T+5 · 6mo ago +13.04%α +11.05% · $5.81
  4. T+20 · 6mo ago +145.91%α +140.96% · $12.64
  5. T+60 · 4mo ago +202.72%α +199.98% · $15.56

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Q32 Bio reported Q1 2026 net loss of $7.6M ($0.54/share), narrower than the $11.0M loss in Q1 2025, driven by lower R&D and G&A expenses. Cash runway extended into 1H 2028 following a $10.5M RDO and $14.2M ATM proceeds, with the key catalyst being mid-2026 topline data from the SIGNAL-AA Phase 2a trial for bempikibart. The sequential improvement in cash burn and extended runway are positive, but the stock remains a binary event driven by clinical data.

Key Financial Metrics

EPS
−$0.54
est −$0.52 · -3.9%
Rating
in line

Key Facts

  • Net loss narrowed to $7.6M ($0.54/share) in Q1 2026 from $11.0M ($0.90/share) in Q1 2025
  • Cash and cash equivalents of $50.8M as of March 31, 2026, plus $14.2M in ATM proceeds received after quarter-end
  • Cash runway extended into first half of 2028, from prior guidance of Q4 2027
  • Bempikibart 36-week topline data from Part B of SIGNAL-AA Phase 2a trial on track for mid-2026
  • First patient dosed in Part B open-label extension (OLE)
  • R&D expenses fell to $3.2M from $7.1M YoY due to reduced headcount and lower clinical spend
  • G&A expenses fell to $4.5M from $5.1M YoY due to lower legal and consulting costs
  • ATM program raised $14.2M in gross proceeds after quarter-end; $75M ATM filed April 24, 2026

Financial Impact

Net loss improved by $3.4M YoY; cash position increased $2.5M sequentially; $24.7M in total capital raised (RDO + ATM) in Q1 2026

net losscash and cash equivalentsoperating expenses

Risk Factors

  • Phase 2a topline data may fail to meet efficacy endpoints, causing significant downside
  • ATM overhang of up to $75M could pressure stock price regardless of clinical outcomes
  • Pre-revenue biotech with no approved products; any clinical setback could threaten viability
  • Small open-label trial (33 patients) limits statistical robustness of efficacy signals

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-205006
Document: qttb-20260505.htm0001193125-26-205006
Document: 0001193125-26-205006-index-headers.html0001193125-26-205006
Document: 0001193125-26-205006-index.html0001193125-26-205006
Document: 0001193125-26-205006.txt0001193125-26-205006
8-K Data (Synthetic)0001193125-26-205006

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026